According to in vitro and in vivo investigations, ATL not only slows cell migration and decreases CTGF release in triple-negative breast cancer cells, but also reduces CTGF expression in fibroblasts and increases the susceptibility of triple-negative breast cancer cells to paclitaxel. Here, CCN2 is linked to triple-negative breast carcinoma.